Genevant Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Genevant Sciences's estimated annual revenue is currently $7.9M per year.
- Genevant Sciences's estimated revenue per employee is $155,000
Employee Data
- Genevant Sciences has 51 Employees.
- Genevant Sciences grew their employee count by -11% last year.
Genevant Sciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and President | Reveal Email/Phone |
2 | SVP, Alliance Programs, Head QA/RA and Operations | Reveal Email/Phone |
3 | Senior Director, Pharmaceutical Development | Reveal Email/Phone |
4 | Chief Technology Officer | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | Director Chemistry (Technology Development) | Reveal Email/Phone |
7 | Director, Quality Assurance | Reveal Email/Phone |
8 | Director In Vivo Resources | Reveal Email/Phone |
9 | Senior Director, Technology Development | Reveal Email/Phone |
10 | Manager, Technology Development | Reveal Email/Phone |
Genevant Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Genevant Sciences?
Our industry-leading lipid nanoparticle (LNP) platform has enabled clinical development of the most advanced RNA-based therapeutics. Our LNP platform is the only clinically-validated LNP delivery technology with safety and efficacy evaluated in over 400 patients across multiple clinical programs. It is the first and only LNP platform to enable an approved therapy and has enabled the first siRNA NDA submission filing through its licensed use by Alnylam Pharmaceuticals for the delivery of patisiran, a therapy to treat patients with hereditary ATTR amyloidosis. We intend to use our leadership position in LNP and the strength of the platform's intellectual property to develop our own LNP products and to pursue multiple partnership opportunities.
keywords:N/A
N/A
Total Funding
51
Number of Employees
$7.9M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Genevant Sciences News
... Inc., Appoints Highly Accomplished Life Science Executive, ... Officer for Genevant Sciences, a lipid nanoparticle delivery company,...
... are - Precision NanoSystems, Evonik Industries, Merck KGaA, Corden Pharma, Moderna, Genevant Sciences, Exelead and Avanti Polar Lipids.
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.2M | 51 | -15% | N/A |
#2 | $11.5M | 51 | 2% | N/A |
#3 | $8.8M | 51 | 6% | N/A |
#4 | $14.8M | 51 | -4% | N/A |
#5 | $6.4M | 51 | -12% | $46.4M |